Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

PURPOSE: Studies of diffuse large B-cell lymphoma (DLBCL) are typically evaluated by using a time-to-event approach with relapse, re-treatment, and death commonly used as the events. We evaluated the timing and type of events in newly diagnosed DLBCL and compared patient outcome with reference popul...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Maurer, Matthew J., Ghesquières, Hervé, Jais, Jean-Philippe, Witzig, Thomas E., Haioun, Corinne, Thompson, Carrie A., Delarue, Richard, Micallef, Ivana N., Peyrade, Frédéric, Macon, William R., Jo Molina, Thierry, Ketterer, Nicolas, Syrbu, Sergei I., Fitoussi, Olivier, Kurtin, Paul J., Allmer, Cristine, Nicolas-Virelizier, Emmanuelle, Slager, Susan L., Habermann, Thomas M., Link, Brian K., Salles, Gilles, Tilly, Hervé, Cerhan, James R.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Clinical Oncology 2014
Θέματα:
ORIGINAL REPORTS
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3965261/
https://ncbi.nlm.nih.gov/pubmed/24550425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.51.5866
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια